key: cord-0910445-6m3gtn1q authors: Brookmeyer, Ron title: Commentary on the role of statisticians in pandemics date: 2021-05-08 journal: Stat Med DOI: 10.1002/sim.8935 sha: 32d9cfd92ab236994234a5b82fedf241022f2914 doc_id: 910445 cord_uid: 6m3gtn1q nan incomplete and unreliable than counts of AIDS cases because of the scarcity of COVID-19 tests early in the pandemic and changing patterns of who shows up for tests. COVID-19 modeling has appropriately focused on the transmission dynamics of infection. Transmission models such as susceptible-exposed-infected -recovered models rely on many assumptions such as how long people remain contagious, and rates of contact between persons, seasonality effects, and the introduction and effectiveness of infection control strategies such as physical distancing, wearing of masks or lockdowns. Agent-based modeling and simulations are important tools for implementing transmission models. 7 However, outputs from transmission models represented by smooth colorful curves can provide a false sense of precision and hide uncertainties. Builders of these models need to work especially hard to communicate both to the general public and policy makers the key assumptions that they relied upon. Unfortunately, no guidelines have been published to standardize the results of epidemic prediction models. 8 It is critically important that the statistical community advocate for transparency in transmission models. Standards for reporting results from transmission models need to be developed as has been done for clinical trials, observational studies, and systematic reviews. Epidemics present special challenges in estimating time to event distributions (eg, the incubation period distribution). For example, the first study of the incubation period distribution of HIV infection was based on transfusion-associated AIDS cases and statistical methods were needed to address sampling biases in the data due to truncation. Challenges in estimating the incubation period of COVID 19 arise in part because the dates of infection are not known or not known precisely. Widely cited estimates of the COVID-19 incubation period distribution used statistical methods to address these issues. 9, 10 Pandemics present challenges in the design and conduct of therapeutic and prevention trials. 11 For example, in response to the HIV pandemic, statisticians reconsidered traditional approaches to therapeutic clinical trials and acknowledged that a growing epidemic affecting young people requires study design that address the public health urgency. 12 Surrogate markers were considered to shorten the duration of trials. Vaccine trials for highly infectious pathogens present critical design challenges because the size, geographic location, and duration of outbreaks are uncertain. Flexible and responsive vaccine trial designs are required as outbreaks ebb and surge in different locations. 13, 14 Important considerations in designing vaccine trials include the trial target population, the randomization approach (eg, cluster vs individual randomization), and selection of trial endpoints (eg, infection, symptomatic disease, severe clinical disease or death.) There will undoubtedly be future pandemics. When there is a new public health crisis, we do not have the luxury of time. To have public health impact, statisticians must rapidly become knowledgeable about different aspects of the pathogen, the natural history of disease, the completeness and accuracy of public health surveillance data, transmission dynamics of the infection, and therapeutic and prevention developments. Statisticians can contribute to a host of issues including prediction and epidemic modeling, complexities in estimating incubation periods and transmission rates, and challenges in designing and conducting trials. Statisticians can also contribute by engaging with the media to increase public understanding of statistical issues in predicting and responding to pandemics. While the statistical problems of current and future pandemics can be expected to vary, there is no doubt that statisticians and statistical science will continue to make impactful contributions that address the challenges of public health emergencies. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Data sharing not applicable to this article as no datasets were generated or analysed during the current study ORCID Ron Brookmeyer https://orcid.org/0000-0002-8639-3399 AIDS and COVID-19: a tale of two pandemics and the role of statisticians Ed: predictions about where the coronavirus pandemic is going vary widely. can models be trusted? Farr's law applied to AIDS projections Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. medRxiv Caution warranted: using the institute for health metrics and evaluation model for predicting the course of the COVID-19 pandemic AIDS Epidemiology: A Quantitative Approach Simulations for designing and interpreting intervention trials in infectious diseases Identification and evaluation of epidemic prediction and forecasting reporting guidelines: a systematic review and a call for action Estimating incubation period distributions with coarse data The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application Design considerations for AIDS trials Design of vaccine efficacy trials during public health emergencies Creating a framework for conducting randomized clinical trials during disease outbreaks How to cite this article: Brookmeyer R. Commentary on the role of statisticians in pandemics